Search

everythinglearnresearchcommunity

for

Search:↓

This enzyme helps metabolize fatty acids and isoleucine, and could be key in treating neurological diseases and certain cancers.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Certain interactions help prepare the androgen receptor for pairing and activation, which is important for its role in development and disease.

Androgens, male hormones, affect physical and mental functions, with a decrease leading to health issues like muscle loss, bone disease, and depression, and more research is needed on long-term effects and treatments.

Baldness (androgenic alopecia) could be a risk factor for prostate cancer.

A castrated dog developed hair loss and prostate issues from long-term exposure to estrogen cream.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.

Urologic diseases and treatments in older men can negatively affect fertility, and doctors should talk to patients about this.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Certain gene combinations may affect prostate cancer risk, and GSTP1 methylation is linked to tumor aggressiveness.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.

CEC levels may be a useful marker for predicting prostate cancer progression.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

PAK4 is crucial in cancer progression, brain development, and could be a therapeutic target, especially through the PAK4-CREB axis.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Serum triglyceride levels are not linked to prostate cancer risk.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

Flutamide rarely causes liver toxicity in prostate cancer patients.